A- A A+

Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. 

Larance B, Degenhardt L, Grebely J, Nielsen S, Bruno R, Dietze P, Lancaster K, Larney S, Santo T Jr, Shanahan M, Memedovic S, Ali R, Farrell M. 

Addiction. 2020 Jul;115(7):1295-1305. doi: 10.1111/add.14941. Epub 2020 Feb 5. PMID: 31860767; PMCID: PMC7292758.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292758/

Increased Treatment Engagement and Adherence: Flexible Management with Prolonged-Release Buprenorphine in Treatment of Opioid Dependence. 

Hard B. 

Case Rep Psychiatry. 2021 Feb 27;2021:6657350. doi: 10.1155/2021/6657350. PMID: 33728083; PMCID: PMC7936910.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7936910/

Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies. 

Fava M, Thase ME, Trivedi MH, Ehrich E, Martin WF, Memisoglu A, Nangia N, Stanford AD, Yu M, Pathak S. 

Mol Psychiatry. 2020 Jul;25(7):1580-1591. doi: 10.1038/s41380-018-0284-1. Epub 2018 Oct 29. PMID: 30374191; PMCID: PMC7303008.

https://www.nature.com/articles/s41380-018-0284-1

Evaluation of Drug‐Drug Interaction Liability for Buprenorphine Extended‐Release Monthly Injection Administered by Subcutaneous Route. 

Kharidia, J., Howgate, E.M., Laffont, C.M., Liu, Y. and Young, M.A. (2021), 

Clinical Pharmacology in Drug Development. doi.org/10.1002/cpdd.934

https://accp1.onlinelibrary.wiley.com/doi/10.1002/cpdd.934

Oxybutynin treatment for buprenorphine-naloxone-induced hyperhidrosis. 

McCormack L, Ponce J, Chatterjee A, Tan JK. 

JAAD Case Rep. 2021 Jan 11;10:22-24. doi: 10.1016/j.jdcr.2020.12.031. PMID: 33732840; PMCID: PMC7941000.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941000/

Micro-dosing Intravenous Buprenorphine to Rapidly Transition From Full Opioid Agonists. 

Thakrar AP, Jablonski L, Ratner J, Rastegar DA. 

J Addict Med. 2021 Mar 19. doi: 10.1097/ADM.0000000000000838. Epub ahead of print. PMID: 33758112.

Abstract

https://pubmed.ncbi.nlm.nih.gov/33758112/

SUBOXONE® Sublingualfilm ist jetzt für die Behandlung der Opioidabhängigkeit verfügbar

Mannheim - Indivior (INDV) gab heute bekannt, dass Suboxone® Sublingualfilm (Buprenorphin und Naloxon) jetzt in Deutschland für die Substitutionstherapie bei Opioidabhängigkeit im Rahmen medizinischer, sozialer und psychotherapeutischer Maßnahmen verfügbar ist. Suboxone wird angewendet bei Erwachsenen und Jugendlichen über 15 Jahren, die einer Suchtbehandlung zugestimmt haben.

Das Medikament enthält Buprenorphin, einen partiellen Opioid-Agonisten, und Naloxon, einen Opioid-Antagonisten, und wird unter die Zunge (sublingual) platziert oder an die Innenseite einerWange (buccal) gelegt, und dort belassen, bis er sich vollständig aufgelöst hat. (Indivio, Pressemitteilung, 12.03.2021)

PM_Indivior_Suboxone Sublingualfilm_03_2021

The administration of the opioid buprenorphine decreases motivational error signals

D.M. Pfabigan, M. Rütgen, S.L. Kroll, I. Riečanský, C. Lamm,

Psychoneuroendocrinology, 2021, 105199, ISSN 0306-4530, doi.org/10.1016/j.psyneuen.2021.105199. In Press, Journal Pre-proof

https://www.sciencedirect.com/science/article/pii/S0306453021000731

RBP-6000: a rationally designed prolonged-release buprenorphine formulation

Authors: Wiest K., Shaya G., Somaini L., and Greenwald M.

Summary: Background. RBP-6000 (Sublocade®; Subutex Prolonged Release Solution for Injection®) is a monthly prolonged-release subcutaneous formulation of buprenorphine that has been rationally designed to achieve sustained mu-opioid receptor (MOR) occupancy at levels that suppress withdrawal symptoms, drug-liking and craving, which drive addiction

Heroin Addiction and Related Clinical Problems, Published Ahead of Print, January 18, 2021

https://www.heroinaddictionrelatedclinicalproblems.org/download-article.php?idarticolodoi=Adoi0000310

Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial. 

Wong JSH, Nikoo M, Westenberg JN, Suen JG, Wong JYC, Krausz RM, Schütz CG, Vogel M, Sidhu JA, Moe J, Arishenkoff S, Griesdale D, Mathew N, Azar P. 

Addict Sci Clin Pract. 2021 Feb 12;16(1):11. doi: 10.1186/s13722-021-00220-2. PMID: 33579359; PMCID: PMC7881636. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881636/

Buprenorphine Microdose Induction for the Management of Prescription Opioid Dependence. 

Robbins JL, Englander H, Gregg J. 

J Am Board Fam Med. 2021 Feb;34(Suppl):S141-S146. doi: 10.3122/jabfm.2021.S1.200236. PMID: 33622829.

https://www.jabfm.org/content/34/Supplement/S141.long

Opioid overdose reduced in patients taking buprenorphine

Study indicates the drug is effective in opioid users who also take benzodiazepines for anxiety, other conditions. (Washington University School of Medicine, 02.03.2021)

https://medicine.wustl.edu/news/buprenorphine-protects-against-opioid-overdoses-even-in-benzodiazepine-users/

Suchtrehabilitation von Opioidabhängigen in Behandlung mit injizierbarem, subkutanem Depot-Buprenorphin (ARIDE) - Addiction recovery of opioid dependent patients treated with injectable subcutaneous depot buprenorphine (ARIDE)

Wir freuen uns über Ihr Interesse an der ARIDE-Studie, die unter Leitung von Herrn Prof. Jens Reimer und Dr. Bernd Schulte durch das Zentrum für Interdisziplinäre Suchtforschung der Universität Hamburg (ZIS) durchgeführt wird. 

Sie finden auf diesen Seiten Informationen zum Ablauf der Studie sowohl in kompakter Form als auch das ausführliche Studienprotokoll und weitergehende Hintergrundinformationen.

https://www.aride-studie.de/

Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone. 

Rolland B, Trojak B, Nourredine M, Bachellier J, Chappuy M, Bendimerad P, Kosim M, Hjelmström P, Meroueh F, Nubukpo P, Brousse G. 

Drug Alcohol Depend. 2021 Mar 1;220:108492. doi: 10.1016/j.drugalcdep.2020.108492. Epub 2021 Jan 8. PMID: 33482572.

https://www.sciencedirect.com/science/article/pii/S0376871620306578

Intravenous Buprenorphine Micro-dosing Induction in a Patient on Methadone Treatment: A Case Report. 

Crane K, Snead J, Stanley R, Avery J, Ghosh SM, Mints G. 

Psychosomatics. 2020 Jul 25:S0033-3182(20)30213-9. doi: 10.1016/j.psym.2020.07.004. Epub ahead of print. PMID: 33451853; PMCID: PMC7381397.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381397/

Microdosing and standard-dosing take-home buprenorphine from the emergency department: A feasibility study. 

Moe J, Badke K, Pratt M, Cho RY, Azar P, Flemming H, Sutherland KA, Harvey B, Gurney L, Lockington J, Brasher P, Gill S, Garrod E, Bath M, Kestler A. 

J Am Coll Emerg Physicians Open. 2020 Oct 20;1(6):1712-1722. doi: 10.1002/emp2.12289. PMID: 33392580; PMCID: PMC7771760.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771760/

Effectiveness of incentivised adherence and abstinence monitoring in buprenorphine maintenance: a pragmatic, randomised controlled trial. 

Elarabi, H. F., Shawky, M., Mustafa, N., Radwan, D., Elarasheed, A., Yousif Ali, A., Osman, M., Kashmar, A., Al Kathiri, H., Gawad, T., Kodera, A., Al Jneibi, M., Adem, A., Lee, A. J., and Marsden, J. (2021) 

Addiction, doi.org/10.1111/add.15394. 

https://onlinelibrary.wiley.com/doi/full/10.1111/add.15394

Individual and structural correlates of willingness for intravenous buprenorphine treatment among people who inject sublingual buprenorphine in France. 

Mezaache, S., Carrieri, P., Briand-Madrid, L. et al 

Harm Reduct J 18, 11 (2021). doi.org/10.1186/s12954-021-00460-0

https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-021-00460-0

Addiction Recovery Among Opioid-Dependent Patients Treated With Injectable Subcutaneous Depot Buprenorphine: Study Protocol of a Non-randomized Prospective Observational Study (ARIDE). 

Schulte B, Lehmann K, Schmidt CS, Rühling E, Weber B, Schäfer I, Reimer J, Verthein U. 

Front Psychiatry. 2020 Dec 8;11:580863. doi: 10.3389/fpsyt.2020.580863. PMID: 33363483; PMCID: PMC7752950.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752950/

Buprenorphine-naloxone microdosing: Tool for opioid agonist therapy induction. 

Marwah R, Coons C, Myers J, Dumont Z. 

Can Fam Physician. 2020 Dec;66(12):891-894. French. doi: 10.46747/cfp.6612891. Erratum in: Can Fam Physician. 2020 Dec;66(12):e302-e306. PMID: 33334955; PMCID: PMC7745932.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745932/

Case Series: Rapid Induction Onto Long Acting Buprenorphine Injection for High Potency Synthetic Opioid Users. 

Mariani JJ, Mahony A, Iqbal MN, Luo SX, Naqvi NH, Levin FR.

Am J Addict. 2020 Jul;29(4):345-348. doi: 10.1111/ajad.13018. Epub 2020 Mar 13. PMID: 32167629; PMCID: PMC7383940.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383940/

Buprenorphine-naloxone "microdosing": an alternative induction approach for the treatment of opioid use disorder in the wake of North America's increasingly potent illicit drug market. 

Randhawa PA, Brar R, Nolan S. 

CMAJ. 2020 Jan 20;192(3):E73. doi: 10.1503/cmaj.74018. PMID: 31959660; PMCID: PMC6970598.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6970598/

Case report: Successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach. 

Rozylo J, Mitchell K, Nikoo M, Durante SE, Barbic SP, Lin D, Mathias S, Azar P. 

Addict Sci Clin Pract. 2020 Jan 15;15(1):2. doi: 10.1186/s13722-020-0177-x. PMID: 31941547; PMCID: PMC6964069.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964069/

A review of the pharmacogenomics of buprenorphine for the treatment of opioid use disorder. 

Seguí HA, Melin K, Quiñones DS, Duconge J. 

J Transl Genet Genom. 2020;4:263-277. doi: 10.20517/jtgg.2020.35. Epub 2020 Jul 30. PMID: 33274315; PMCID: PMC7709797.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709797/

Patient-Reported Outcomes, Experiences and Satisfaction with Weekly and Monthly Injectable Prolonged-Release Buprenorphine. 

Parsons G, Ragbir C, D'Agnone O, Gibbs A, Littlewood R, Hard B. 

Subst Abuse Rehabil. 2020 Nov 2;11:41-47. doi: 10.2147/SAR.S266838. PMID: 33173372; PMCID: PMC7648142.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648142/

Beyond Buprenorphine: Models of Follow-up Care for Opioid Use Disorder in the Emergeny Department.

Martin A, Butler K, Chavez T, Herring A, Wakeman S, Hayes BD, Raja A.

West J Emerg Med. 2020 Nov 2;21(6):257-263. doi: 10.5811/westjem.2020.7.46079. PMID: 33207174; PMCID: PMC7673896.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673896/

Sexual Adverse Effects and Erectile Dysfunction During Buprenorphine/Naloxone Combination Treatment for Opioid Use Disorders. 

Bestepe EE, Tunali N, Sarıdoğan GE. 

Neuropsychiatr Dis Treat. 2020 Nov 12;16:2695-2705. doi: 10.2147/NDT.S276708. PMID: 33209025; PMCID: PMC7669501.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7669501/

Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study. 

Ling W, Nadipelli VR, Aldridge AP, Ronquest NA, Solem CT, Chilcoat H, Albright V, Johnson C, Learned SM, Mehra V, Heidbreder C.

J Addict Med. 2020 Sep/Oct;14(5):e233-e240. doi: 10.1097/ADM.0000000000000647. PMID: 32187112; PMCID: PMC7547872.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547872/

How do individuals fare long-term after receiving long-acting, injectable formulations of buprenorphine for opioid use disorder?

Evidence has mounted regarding the short-term effectiveness of long-acting buprenorphine formulations for opioid use disorder, but knowledge about longer-term psychosocial and other health outcomes have been lacking. This paper reports 12-month outcomes from a study of individuals who had previously taken part in one of two, year-long, clinical trials of a long-acting, injectable formulation of buprenorphine for moderate to severe opioid use disorder. (RRI – Recovery Research Institute, USA, November 2020)

https://www.recoveryanswers.org/research-post/long-term-effects-long-acting-injectable-buprenorphine-opioid-use-disorder/

Reconsidering the Usefulness of Adding Naloxone to Buprenorphine. 

Blazes CK, Morrow JD. 

Front Psychiatry. 2020 Sep 11;11:549272. doi: 10.3389/fpsyt.2020.549272. PMID: 33061915; PMCID: PMC7517938.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7517938/